Relapsed or refractory multiple myeloma
Clinical trials for Relapsed or refractory multiple myeloma explained in plain language.
Never miss a new study
Get alerted when new Relapsed or refractory multiple myeloma trials appear
Sign up with your email to follow new studies for Relapsed or refractory multiple myeloma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug combo outsmart Hard-to-Treat myeloma?
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New 'Off-the-Shelf' CAR-T therapy takes on Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase trial is testing DQ1001, a ready-made CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is designed for patients whose multiple myeloma has returned or stopped responding to at least three prior treatments. The study will enroll …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase 1 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-stage trial tests the safety of a new CAR T-cell therapy, UF-KURE-BCMA, in 12 adults with multiple myeloma that has returned or not responded to other treatments. The therapy uses specially engineered immune cells to target and attack cancer cells. The main goal is to …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase 1 • Sponsor: Kure Cells, INC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC